RICHARD A RUDICK, MD
Neurology at Euclid Ave, Cleveland, OH

6366797, Apr 2, 2002

Aug 24, 1999

09/382056

Elizabeth Fisher - Cleveland Heights OH
Richard A. Rudick - Solon OH

The Cleveland Clinic Foundation - Cleveland OH

A61B 500

600410, 382128, 128922

A method of analyzing medical image data to measure brain atrophy and determine the severity and progression of multiple sclerosis or other condition which leads to neurodegeneration or axonal damage is provided. Magnetic resonance image data representing a brain of a subject is provided and a brain surface contour is automatically identified by separating the brain from other connected structures in the image data. A total volume within the brain surface contour is calculated. A brain volume is then determined within the surface contour which excludes fluid filled regions and accounts for partial volume effects. The brain volume is then normalized by the total contour volume which generates a brain parenchymal fraction. The brain parenchymal fraction serves as a reliable measurement of brain atrophy and assists in determining the severity and progression of multiple sclerosis or other condition which leads to neurodegeneration or axonal damage.

2013008, Apr 11, 2013

Jun 17, 2011

13/704752

Richard A. Rudick - Solon OH, US
Richard M. Ransohoff - Shaker Heights OH, US

C12Q 1/68

424 856, 506 9

A method is provided for determining the efficacy of interferon-beta (IFN-β) therapy in a subject with multiple sclerosis. One step of the method can include obtaining a biological sample from the subject. After obtaining the biological sample, the expression level of at least one interferon-regulated gene (IRG) and/or variant thereof can be determined. Increased or decreased expression of the at least one IRG and/or variant thereof as compared to a control may indicate that the subject will respond poorly to IFN-β therapy.